Review links linagliptin to lower kidney risk in diabetes

11/6/2012 | Medscape (free registration)

An analysis presented at Kidney Week 2012 showed type 2 diabetes patients who took linagliptin were 16% less likely to develop micro- and macroalbuminuria, chronic kidney disease and acute renal failure and showed lower risk of all-cause mortality compared with those in the placebo group.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA